# Drug Interaction Classification System

Drug interactions occur when the effect of one medication is altered by the presence of another drug, food, beverage, or environmental agent. Systematic classification of these interactions enables clinicians to anticipate adverse outcomes and adjust treatment plans proactively.

## Interaction Severity Levels

| Severity | Clinical Significance | Action Required |
|----------|----------------------|-----------------|
| Contraindicated | Life-threatening; combination must be avoided | Do not co-prescribe; select alternative therapy |
| Major | May cause significant harm or require intervention | Use only if benefit outweighs risk; monitor closely |
| Moderate | May exacerbate condition or require dose adjustment | Monitor for adverse effects; adjust doses as needed |
| Minor | Limited clinical significance; minimal risk | Routine monitoring; counsel patient on symptoms |

## Pharmacokinetic Interactions

Pharmacokinetic interactions alter the absorption, distribution, metabolism, or excretion of a drug, changing its plasma concentration without directly affecting its mechanism of action.

### Absorption Interactions

Drugs that alter gastrointestinal pH can affect the absorption of pH-dependent medications. Proton pump inhibitors reduce stomach acidity, decreasing the absorption of drugs like ketoconazole that require an acidic environment for dissolution. Chelation occurs when divalent cations in antacids bind to fluoroquinolone antibiotics, forming insoluble complexes that reduce bioavailability by up to 90%.

### Metabolism Interactions (CYP450 System)

The cytochrome P450 enzyme system is responsible for metabolizing approximately 75% of all drugs. Interactions involving CYP450 enzymes are among the most clinically significant.

| CYP Enzyme | Common Substrates | Notable Inhibitors | Notable Inducers |
|------------|-------------------|-------------------|-----------------|
| CYP3A4 | Simvastatin, cyclosporine, midazolam | Ketoconazole, ritonavir, grapefruit | Rifampin, carbamazepine, St. John's Wort |
| CYP2D6 | Codeine, metoprolol, fluoxetine | Paroxetine, quinidine, bupropion | Dexamethasone (weak) |
| CYP2C19 | Omeprazole, clopidogrel, diazepam | Fluconazole, fluvoxamine | Rifampin, efavirenz |
| CYP1A2 | Theophylline, caffeine, warfarin (minor) | Fluvoxamine, ciprofloxacin | Smoking, charbroiled foods |

Enzyme inhibitors increase substrate plasma levels by reducing metabolic clearance, potentially causing toxicity. Enzyme inducers accelerate metabolism, reducing drug efficacy and potentially leading to therapeutic failure.

## Pharmacodynamic Interactions

Pharmacodynamic interactions occur when two drugs affect the same physiological system, producing additive, synergistic, or antagonistic effects without altering plasma concentrations.

Combining two drugs with sedative properties, such as benzodiazepines and opioid analgesics, produces additive central nervous system depression that can result in respiratory failure. Serotonin syndrome may occur when multiple serotonergic agents are co-administered, including selective serotonin reuptake inhibitors, tramadol, and certain migraine medications.

QT interval prolongation is a pharmacodynamic interaction of particular concern. Multiple drugs that individually prolong the QT interval can produce dangerous additive effects, increasing the risk of torsades de pointes, a potentially fatal ventricular arrhythmia.

## Clinical Decision Support

Modern electronic prescribing systems integrate drug interaction databases that flag potential interactions at the point of ordering. Effective clinical decision support systems stratify alerts by severity to reduce alert fatigue, a phenomenon where clinicians override warnings due to excessive low-priority notifications. Institutions should regularly review override rates and refine alert thresholds to maintain clinical relevance.
